OR WAIT 15 SECS
Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.
The locations will feature end-to-end bioprocessing centers and will be in Shanghai, China and Boston, MA.
Following the successful opening of an end-to-end bioprocessing plant in Martillac, France in 2012, MilliporeSigma announced on Jan. 10, 2016 that it will open two more bioprocessing locations, one of which will be in China and the other in Boston, Massachusetts. The new locations will offer cell-line development services, process development expertise, and non-GMP clinical production services. The main difference between the new locations and the existing Martillac site is that the France location is a GMP facility that manufactures clinical-stage batches. The France site is the main biodevelopment center worldwide, according to Karen Tiano, head of media relations at MilliporeSigma.
According to a company press release, the Boston and Shanghai sites are non-GMP. The locations will feature the full suite of MilliporeSigma technologies. The suite includes single-use, sterile connectors, single-use disposable modules for viral clearance, tangential flow filtration cassettes for filtration, and a gene-editing technology to confer viral resistance to Chinese hamster ovary (CHO) cell lines.